SPRB vs ACRS vs NKTR vs PTGX vs IMVT

For growth investors, Nektar Therapeutics (NKTR) is the stronger pick with -43.

9% revenue growth year-over-year, versus -100. 0% for Spruce Biosciences, Inc. (SPRB). Analysts rate Aclaris Therapeutics, Inc. (ACRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +238. 8%, compared to -95. 1% for Spruce Biosciences, Inc. (SPRB). Over 10 years, the gap is even starker: PTGX returned +749. 2% versus SPRB's -95. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aclaris Therapeutics, Inc.

(ACRS) is the lower-risk stock at 0. 22β versus Nektar Therapeutics's 1. 80β — meaning NKTR is approximately 720% more volatile than ACRS relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nektar Therapeutics (NKTR) is pulling ahead at -43.

9% versus -100. 0% for Spruce Biosciences, Inc. (SPRB). On earnings-per-share growth, the picture is similar: Aclaris Therapeutics, Inc. grew EPS 69. 0% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, PTGX leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Spruce Biosciences, Inc.

(SPRB) is the more profitable company, earning 0. 0% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SPRB leads at 0. 0% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ACRS: 118.

1% to $10. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), +749. 2% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTGX: +749. 2%, NKTR: -59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.